1976
A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors
Robinson R, DeVita V, Levy H, Baron S, Hubbard S, Levine A. A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors. Journal Of The National Cancer Institute 1976, 57: 599-602. PMID: 978771, DOI: 10.1093/jnci/57.3.599.Peer-Reviewed Original ResearchConceptsSolid tumorsSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvic transaminaseSeparate drug trialsObjective tumor responseDetectable serum levelsRoute of administrationChronic myelogenous leukemiaLow serum concentrationsGlutamic oxaloacetic transaminaseGlutamic pyruvic transaminasePolyriboinosinic-polyribocytidylic acidPoly I-poly CInducers of interferonCoagulation abnormalitiesSerum levelsMultiple dosesSerum concentrationsTumor responseAcute leukemiaDrug trialsBlast crisisMyelogenous leukemiaTransient elevationDrug dose
1973
Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)
Young R, Walker M, Canellos G, Schein P, Chabner B, Devita V. Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu). Cancer 1973, 31: 1164-1169. PMID: 4705154, DOI: 10.1002/1097-0142(197305)31:5<1164::aid-cncr2820310519>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsPrior therapyMultiple dosesClinical trialsCumulative marrow toxicityObjective therapeutic responseHepatic side effectsSingle oral doseReticulum cell sarcomaInitial clinical trialsPrimary brain tumorsPreliminary clinical trialsMarrow suppressionHodgkin's diseaseOral doseCell sarcomaMarrow toxicityPrimary toxicityTherapeutic responseBrain tumorsSide effectsPatientsConsiderable toxicitySubsequent courseMeCCNUDoses